Response to Neoadjuvant Chemoradiotherapy as a Predictor of Long-Term Survival in Patients with Locally Advanced Rectosigmoid Junction Cancer: An Analysis Based On SEER Database
Abstract
Background: Neoadjuvant chemoradiotherapy is recommended to locally advanced rectal cancer, especially for the lower and middle ones. However, the role of neoadjuvant chemoradiotherapy in rectosigmoid junction cancer remains undetermined. We investigated whether patients with a good response to neoadjuvant chemoradiotherapy will have a relatively better long-term survival compared with those with no response.
Methods: Overall, 1325 patients diagnosed with locally advanced rectosigmoid junction cancer from Surveillance, Epidemiology, and End-Results (SEER) cancer registry database (2004-2014, America) were selected. All of them had received neoadjuvant chemoradiotherapy and were evaluated by Collaborative Stage Data Collection System. We performed Kaplan–Meier univariate analysis and Cox regression multivariate analysis models to estimate the potential prognostic factors of long-term survival outcomes. Response to neoadjuvant chemoradiotherapy and histological type of tumor were the two prognostic factors.
Results: The 5-year OS was 78.1% in responders, and 63.4% in nonresponders. In addition the 5-year DSS was 85.1% in responders, and 72.9% in nonresponders.
Conclusion: Based on SEER database in locally advanced rectosigmoid junction cancer, patients with a good response to neoadjuvant chemoradiotherapy could have a benefit of long-term survival.
2. Kapiteijn E, Marijnen CA, Nagtegaal ID, et al (2001). Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med, 345(9): 638-46.
3. van Gijn W, Marijnen CA, Nagtegaal ID, et al (2011). Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol, 12(6): 575-82.
4. Song JH, Jeong JU, Lee JH, et al (2017). Preoperative chemoradiotherapy versus postoperative chemoradiotherapy for stage II-III resectable rectal cancer: a meta-analysis of randomized controlled trials. Radiat Oncol J, 35(3): 198-207.
5. Aschele C, Cionini L, Lonardi S, et al (2011). Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol, 29(20): 2773-80.
6. Mukai M, Kishima K, Yamazaki M, et al (2011). Stage II/III cancer of the rectosigmoid junction: an independent tumor type? Oncol Rep, 26(3): 737-41.
7. Guan X, Jiang Z, Ma T, et al (2016). Radiotherapy dose led to a substantial prolongation of survival in patients with locally advanced rectosigmoid junction cancer: a large population based study. Oncotarget, 7(19): 28408-19.
8. McDevitt J, Comber H, Walsh PM (2017). Colorectal cancer incidence and survival by sub-site and stage of diagnosis: a population-based study at the advent of national screening. Ir J Med Sci, 186(1): 113-121.
9. Chan E, Wise PE, Chakravarthy AB (2012). Controversies in radiation for upper rectal cancers. J Natl Compr Canc Netw, 10(12): 1567-72.
10. Sebag-Montefiore D, Stephens RJ, Steele R, et al (2009). Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet, 373(9666): 811-20.
11. Rödel C, Liersch T, Becker H, et al (2012). Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol, 13(7): 679-87.
12. Kim KH, Shin SJ, Cho MS, (2016). A phase II study of preoperative mFOLFOX6 with short-course radiotherapy in patients with locally advanced rectal cancer and liver-only metastasis. Radiother Oncol, 118(2): 369-74.
13. Eisenhauer EA, Therasse P, Bogaerts J, et al (2009). New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer, 45(2): 228-47.
14. Ruo L, Tickoo S, Klimstra DS, et al (2002). Long-term prognostic significance of extent of rectal cancer response to preoperative radiation and chemotherapy. Ann Surg, 236(1): 75-81.
15. Maas M, Nelemans PJ, Valentini V, et al (2010). Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol, 11(9): 835-44.
| Files | ||
| Issue | Vol 52 No 9 (2023) | |
| Section | Original Article(s) | |
| DOI | https://doi.org/10.18502/ijph.v52i9.13575 | |
| Keywords | ||
| Rectosigmoid junction cancer Neoadjuvant therapy Chemoradiotherapy Long-term survival Treatment outcome | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
